CY1109463T1 - Πεπτιδια kdr και εμβολια που τα περιλαμβανουν - Google Patents
Πεπτιδια kdr και εμβολια που τα περιλαμβανουνInfo
- Publication number
- CY1109463T1 CY1109463T1 CY20091100856T CY091100856T CY1109463T1 CY 1109463 T1 CY1109463 T1 CY 1109463T1 CY 20091100856 T CY20091100856 T CY 20091100856T CY 091100856 T CY091100856 T CY 091100856T CY 1109463 T1 CY1109463 T1 CY 1109463T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- amino acid
- kdr
- shapes
- vaccines including
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4208—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει εννεαπεπτίδια επιλεγόμενα από πεπτίδια περιλαμβάνοντα την αλληλουχία αμινοξέων ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 2, 3, 5, 8, 11 ή 12• εννεαπεπτίδια ή δεκαπεπτίδια επιλεγόμενα από τα πεπτίδια που περιλαμβάνουν την αλληλουχία αμινοξέων ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 29, 30, 33, 34, 40 ή 46• και πεπτίδια με ικανότητα επαγωγής κυτταροτοξικών κυττάρων Τ στα οποία ένα, δύο ή περισσότερα αμινοξέα αντικαθίστανται ή προστίθενται στις προαναφερθείσες αλληλουχίες αμινοξέων, καθώς και φάρμακα για την αγωγή ή την πρόληψη όγκων, όπου τα φάρμακα περιλαμβάνουν αυτά τα πεπτίδια. Τα πεπτίδια της παρούσης εφευρέσεως μπορούν να χρησιμοποιηθούν ως εμβόλια.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002267285 | 2002-09-12 | ||
| JP2003062003 | 2003-03-07 | ||
| JP2003167042 | 2003-06-11 | ||
| EP03795432A EP1548032B9 (en) | 2002-09-12 | 2003-09-12 | Kdr peptides and vaccines comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109463T1 true CY1109463T1 (el) | 2014-08-13 |
Family
ID=31998762
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100856T CY1109463T1 (el) | 2002-09-12 | 2009-08-12 | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν |
| CY20121100072T CY1113379T1 (el) | 2002-09-12 | 2012-01-19 | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100072T CY1113379T1 (el) | 2002-09-12 | 2012-01-19 | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US7514084B2 (el) |
| EP (11) | EP2270042B1 (el) |
| JP (3) | JP3971769B2 (el) |
| CN (5) | CN103951745A (el) |
| AT (2) | ATE432291T1 (el) |
| AU (1) | AU2003264419A1 (el) |
| CY (2) | CY1109463T1 (el) |
| DE (1) | DE60327786D1 (el) |
| DK (6) | DK2267022T3 (el) |
| ES (2) | ES2327040T3 (el) |
| HK (7) | HK1124077A1 (el) |
| PT (2) | PT2014678E (el) |
| SI (2) | SI2014678T1 (el) |
| WO (1) | WO2004024766A1 (el) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60327786D1 (de) | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| JP4628208B2 (ja) * | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| ES2364670T3 (es) * | 2005-02-25 | 2011-09-12 | Oncotherapy Science, Inc. | Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk. |
| JP4931154B2 (ja) | 2005-02-28 | 2012-05-16 | オンコセラピー・サイエンス株式会社 | 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン |
| US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
| CN101283279A (zh) | 2005-07-29 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | 以cdca1-kntc2复合物为靶标的筛选和nsclc治疗方法 |
| ATE534415T1 (de) | 2005-12-13 | 2011-12-15 | Harvard College | Gerüste zur zelltransplantation |
| ES2601432T3 (es) | 2006-08-11 | 2017-02-15 | Life Sciences Research Partners Vzw | Péptidos inmunógenos y su uso en trastornos inmunitarios |
| TWI441648B (zh) * | 2007-01-03 | 2014-06-21 | Oncotherapy Science Inc | Ｆｏｘｐ３胜肽疫苗 |
| ES2405763T3 (es) * | 2007-02-16 | 2013-06-03 | Oncotherapy Science, Inc. | Vacunoterapia para la neovascularización coroidea |
| TWI434853B (zh) * | 2007-04-11 | 2014-04-21 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| TW200908998A (en) * | 2007-06-27 | 2009-03-01 | Oncotherapy Science Inc | Compositions and methods of treating cancer |
| EP4032899A1 (en) | 2007-08-20 | 2022-07-27 | Oncotherapy Science, Inc. | Foxm1 peptide and medicinal agent comprising the same |
| RU2486195C2 (ru) * | 2007-08-20 | 2013-06-27 | Онкотерапи Сайенс, Инк. | Пептид cdca1 и включающее его фармацевтическое средство |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| WO2009102465A2 (en) | 2008-02-13 | 2009-08-20 | President And Fellows Of Harvard College | Continuous cell programming devices |
| AU2009214041A1 (en) | 2008-02-14 | 2009-08-20 | Katholieke Universiteit Leuven | CD4+ T-cells with cytolytic properties |
| CA2715488C (en) | 2008-02-14 | 2019-09-24 | Life Sciences Research Partners Vzw | Immunogenic control of tumours and tumour cells |
| EP2719396B1 (en) | 2008-02-14 | 2017-06-21 | Life Sciences Research Partners VZW | Immunotherapy targeting intracellular pathogens |
| US9044507B2 (en) | 2008-02-14 | 2015-06-02 | Life Sciences Research Partners Vzw | Elimination of immune responses to viral vectors |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| TWI526219B (zh) * | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
| CN104086625B (zh) | 2008-10-22 | 2016-08-31 | 肿瘤疗法科学股份有限公司 | Rab6kifl/kif20a表位肽及包含它的疫苗 |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| TW201032820A (en) * | 2008-12-16 | 2010-09-16 | Oncotherapy Science Inc | ELOVL7 epitope peptides and vaccines containing the same |
| RU2011130796A (ru) * | 2008-12-24 | 2013-01-27 | Онкотерапи Сайенс, Инк. | Пептиды c1orf59 и содержащие их вакцины |
| ES2728998T3 (es) * | 2009-01-08 | 2019-10-29 | Int Inst Cancer Immunology Inc | Nuevo antígeno de cáncer EEF2 |
| BRPI1012312A2 (pt) * | 2009-03-04 | 2017-03-21 | Oncotherapy Science Inc | peptídeos vangl1 e vacinas incluindo os mesmos |
| CA2755342C (en) * | 2009-03-18 | 2017-10-03 | Oncotherapy Science, Inc. | Neil3 peptides and vaccines including the same |
| TW201100090A (en) * | 2009-04-01 | 2011-01-01 | Oncotherapy Science Inc | C6orf167 peptides and vaccines containing the same |
| TWI507204B (zh) * | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| TW201109029A (en) | 2009-06-11 | 2011-03-16 | Oncotherapy Science Inc | Vaccine therapy for choroidal neovascularization |
| CA2768552A1 (en) | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
| TW201200525A (en) * | 2009-12-04 | 2012-01-01 | Oncotherapy Science Inc | MYBL2 peptides and vaccines containing the same |
| TW201136604A (en) | 2009-12-14 | 2011-11-01 | Oncotherapy Science Inc | TMEM22 peptides and vaccines including the same |
| CN102115492B (zh) * | 2010-01-05 | 2013-03-06 | 中国农业科学院北京畜牧兽医研究所 | 血管内皮生长因子受体部分多肽及其应用 |
| BR112012022641A2 (pt) | 2010-03-11 | 2017-02-14 | Oncotherapy Science Inc | peptídeos hjurp e vacinas que incluem os mesmos |
| TW201134480A (en) * | 2010-04-08 | 2011-10-16 | Oncotherapy Science Inc | CLUAP1 peptides and vaccines including the same |
| CN102947325B (zh) * | 2010-04-09 | 2015-04-01 | 肿瘤疗法科学股份有限公司 | Cdca5肽及包含它们的疫苗 |
| TW201211250A (en) * | 2010-09-07 | 2012-03-16 | Oncotherapy Science Inc | VANGL1 peptides and vaccines including the same |
| PT2624873T (pt) | 2010-10-06 | 2020-03-04 | Harvard College | Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais |
| EP2643345B1 (en) | 2010-11-25 | 2021-02-24 | Imnate Sarl | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |
| DK2646546T3 (en) * | 2010-12-02 | 2018-08-06 | Oncotherapy Science Inc | TOMM34 PEPTIDES AND VACCINES CONTAINING THESE |
| GB201201511D0 (en) | 2012-01-30 | 2012-03-14 | Univ Leuven Kath | Modified epitopes for boosting CD4+ T-cell responses |
| EP2823824A4 (en) | 2012-03-09 | 2015-09-16 | Oncotherapy Science Inc | PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE |
| CA2870309C (en) | 2012-04-16 | 2024-02-20 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
| WO2013168820A1 (ja) | 2012-05-11 | 2013-11-14 | 公益財団法人微生物化学研究会 | 抗ｃｘａｄｒ抗体 |
| US9687538B2 (en) | 2012-07-10 | 2017-06-27 | Oncotherapy Science, Inc. | CDCA1 epitope peptides for Th1 cells and vaccines containing the same |
| JP2016502499A (ja) * | 2012-12-04 | 2016-01-28 | オンコセラピー・サイエンス株式会社 | Ｓｅｍａ５ｂペプチドおよびそれを含むワクチン |
| JP6357113B2 (ja) | 2013-02-08 | 2018-07-11 | 株式会社医学生物学研究所 | ヒトｎｒｇ１タンパク質に対する抗体 |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| JP2017042047A (ja) * | 2013-12-06 | 2017-03-02 | オンコセラピー・サイエンス株式会社 | Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン |
| EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| CA3012602A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| JP6604975B2 (ja) * | 2015-02-09 | 2019-11-13 | 株式会社ライフアートビレッジ | 免疫細胞療法のためのペプチドスクリーニング方法 |
| EP3280464A4 (en) | 2015-04-10 | 2018-09-26 | President and Fellows of Harvard College | Immune cell trapping devices and methods for making and using the same |
| US10729791B2 (en) | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| WO2017050966A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| CN105200010B (zh) * | 2015-10-15 | 2019-02-12 | 首都医科大学附属北京佑安医院 | 艾滋病感染者hla-a2特异性ctl细胞的体外培养方法及其专用培养基 |
| JP7138864B2 (ja) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫を再構成するための造血ニッチの再現 |
| SG11201808710UA (en) | 2016-04-19 | 2018-11-29 | Imcyse Sa | Novel immunogenic cd1d binding peptides |
| MA45738A (fr) | 2016-07-13 | 2019-05-22 | Harvard College | Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser |
| CN110612115A (zh) * | 2017-05-19 | 2019-12-24 | 学校法人庆应义塾 | 针对脑神经疾病的肽疫苗和肽疫苗组合物 |
| TW202023581A (zh) | 2018-08-02 | 2020-07-01 | 日商腫瘤療法 科學股份有限公司 | 來自cdca1的胜肽及含有此的疫苗 |
| CN111363026B (zh) * | 2020-03-31 | 2022-03-25 | 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） | 一种增强抗原多肽亲和力和稳定性的方法 |
| KR102711471B1 (ko) * | 2020-08-14 | 2024-09-30 | 서울대학교산학협력단 | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861301A (en) | 1992-02-20 | 1999-01-19 | American Cayanamid Company | Recombinant kinase insert domain containing receptor and gene encoding same |
| US6222012B1 (en) | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
| CN1701814A (zh) * | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k－1 |
| ES2230542T3 (es) * | 1993-03-25 | 2005-05-01 | MERCK & CO., INC. | Inhibidor del factor de crecimiento celular endotelial vascular. |
| CA2225553A1 (en) * | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6080728A (en) * | 1996-07-16 | 2000-06-27 | Mixson; A. James | Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy |
| US5942428A (en) * | 1996-08-21 | 1999-08-24 | Sugen, Inc. | Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| JP3837748B2 (ja) * | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Ｖｅｇｆ結合性ポリペプチド |
| ES2292204T3 (es) * | 1997-06-18 | 2008-03-01 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Receptor de tipo tirosina cinasa humano, kdr. |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| WO1999029715A1 (fr) * | 1997-12-05 | 1999-06-17 | Kyogo Itoh | Derives de peptides d'antigene tumoral |
| WO1999040118A1 (fr) * | 1998-02-04 | 1999-08-12 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps diriges contre le recepteur kdr humain du vegf |
| GB9804121D0 (en) * | 1998-02-26 | 1998-04-22 | Cancer Res Campaign Tech | Anti-angiogenic vaccines: materials and methods relating thereto |
| AU3850299A (en) * | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
| NZ508996A (en) | 1998-06-25 | 2003-09-26 | Kyogo Itoh | Tumor antigen peptides derived from cyclophilin B |
| WO2001012809A2 (en) * | 1999-08-13 | 2001-02-22 | Crucell Holland B.V. | Heterodimeric vegf variants used for inhibiting angiogenesis |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| JP2002267285A (ja) | 2001-03-12 | 2002-09-18 | Denso Corp | 冷房冷蔵装置 |
| JP4068371B2 (ja) | 2001-06-13 | 2008-03-26 | 株式会社トプコン | 手術用顕微鏡 |
| JP3640084B2 (ja) | 2001-11-30 | 2005-04-20 | 日本電気株式会社 | 測位機能を搭載した携帯電話端末 |
| CU23178A1 (es) | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| DE60327786D1 (de) * | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| CA2498191C (en) | 2002-09-18 | 2012-04-10 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| JP4931154B2 (ja) | 2005-02-28 | 2012-05-16 | オンコセラピー・サイエンス株式会社 | 血管内皮増殖因子受容体１に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン |
| ES2405763T3 (es) | 2007-02-16 | 2013-06-03 | Oncotherapy Science, Inc. | Vacunoterapia para la neovascularización coroidea |
| TWI436775B (zh) | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
-
2003
- 2003-09-12 DE DE60327786T patent/DE60327786D1/de not_active Expired - Lifetime
- 2003-09-12 CN CN201410214247.3A patent/CN103951745A/zh active Pending
- 2003-09-12 DK DK10010174.0T patent/DK2267022T3/en active
- 2003-09-12 SI SI200332101T patent/SI2014678T1/sl unknown
- 2003-09-12 AU AU2003264419A patent/AU2003264419A1/en not_active Abandoned
- 2003-09-12 DK DK10010169.0T patent/DK2267021T3/en active
- 2003-09-12 EP EP10010176.5A patent/EP2270042B1/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010171A patent/EP2261247A3/en not_active Withdrawn
- 2003-09-12 EP EP03795432A patent/EP1548032B9/en not_active Expired - Lifetime
- 2003-09-12 EP EP10010173.2A patent/EP2261249B1/en not_active Expired - Lifetime
- 2003-09-12 CN CN2007101802067A patent/CN101139393B/zh not_active Expired - Fee Related
- 2003-09-12 AT AT03795432T patent/ATE432291T1/de active
- 2003-09-12 ES ES03795432T patent/ES2327040T3/es not_active Expired - Lifetime
- 2003-09-12 EP EP08018875A patent/EP2014678B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK10010173.2T patent/DK2261249T3/en active
- 2003-09-12 EP EP10010169.0A patent/EP2267021B1/en not_active Expired - Lifetime
- 2003-09-12 JP JP2004571938A patent/JP3971769B2/ja not_active Expired - Lifetime
- 2003-09-12 EP EP10010172.4A patent/EP2261248B1/en not_active Expired - Lifetime
- 2003-09-12 US US10/527,496 patent/US7514084B2/en not_active Expired - Fee Related
- 2003-09-12 CN CN2007101802052A patent/CN101139392B/zh not_active Expired - Fee Related
- 2003-09-12 AT AT08018875T patent/ATE531729T1/de active
- 2003-09-12 EP EP10010174.0A patent/EP2267022B1/en not_active Expired - Lifetime
- 2003-09-12 PT PT08018875T patent/PT2014678E/pt unknown
- 2003-09-12 EP EP10010170.8A patent/EP2270041B1/en not_active Expired - Lifetime
- 2003-09-12 SI SI200331649T patent/SI1548032T1/sl unknown
- 2003-09-12 EP EP08018897A patent/EP2014679B1/en not_active Expired - Lifetime
- 2003-09-12 PT PT03795432T patent/PT1548032E/pt unknown
- 2003-09-12 DK DK10010175.7T patent/DK2267023T3/en active
- 2003-09-12 EP EP10010175.7A patent/EP2267023B1/en not_active Expired - Lifetime
- 2003-09-12 DK DK03795432T patent/DK1548032T3/da active
- 2003-09-12 CN CN201210430723.6A patent/CN103073620B/zh not_active Expired - Fee Related
- 2003-09-12 DK DK08018875.8T patent/DK2014678T3/da active
- 2003-09-12 WO PCT/JP2003/011722 patent/WO2004024766A1/ja active Application Filing
- 2003-09-12 CN CNB038250810A patent/CN100352843C/zh not_active Expired - Lifetime
- 2003-09-12 ES ES08018875T patent/ES2375299T3/es not_active Expired - Lifetime
-
2007
- 2007-03-08 JP JP2007058127A patent/JP4185143B2/ja not_active Expired - Fee Related
- 2007-05-08 JP JP2007123850A patent/JP4185147B2/ja not_active Expired - Fee Related
-
2009
- 2009-01-16 US US12/355,616 patent/US7695720B2/en not_active Expired - Lifetime
- 2009-04-30 HK HK09104058.2A patent/HK1124077A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104992.7A patent/HK1151036A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104977.6A patent/HK1151032A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK09104475.7A patent/HK1125659A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104996.3A patent/HK1151039A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104995.4A patent/HK1151038A1/xx not_active IP Right Cessation
- 2009-05-15 HK HK11104993.6A patent/HK1151037A1/xx not_active IP Right Cessation
- 2009-08-12 CY CY20091100856T patent/CY1109463T1/el unknown
-
2010
- 2010-02-23 US US12/711,159 patent/US8206719B2/en not_active Expired - Fee Related
-
2012
- 2012-01-19 CY CY20121100072T patent/CY1113379T1/el unknown
- 2012-06-12 US US13/494,930 patent/US8574585B2/en not_active Expired - Fee Related
- 2012-06-12 US US13/494,933 patent/US8574586B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| PT2121731E (pt) | Vacinas peptídicas para cancros que expressam antigénios associados a tumores | |
| CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| BG106008A (en) | Novel lhrh antagonists with improved solubility characteristics | |
| DK1268522T3 (da) | LH-RH-antagonister samt fremstilling deraf og anvendelse deraf som lægemidler | |
| EP4047009A3 (en) | Wdrpuh epitope peptides and vaccines containing the same | |
| DE60024977D1 (de) | Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen | |
| DE50205579D1 (de) | Semi-allogene antitumor-vakzine mit hla-haplo-identischen antigen-präsentierenden zellen | |
| CY1114720T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| CY1117399T1 (el) | Συνθεσεις και μεθοδοι για προληψη και θεραπεια νευροεκφυλιστικων ασθενειων |